Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.31 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7164243 | 0.88 | PLG (0.35) | NR1H2TSHRCYP3A4KDM4ECHRNB2 | |
| SCHEMBL6327750 | 0.88 | TSHR (0.35) | NR1H2TSHRCYP3A4KDM4ECHRNB2 | |
| SCHEMBL7162429 | 0.88 | TSHR (0.35) | NR1H2TSHRCYP3A4KDM4ECHRNB2 | |
| SCHEMBL7164726 | 0.88 | TSHR (0.35) | NR1H2TSHRCYP3A4KDM4ECHRNB2 | |
| SCHEMBL6328305 | 0.85 | NR1H2 (0.36) | NR1H2TSHRCYP3A4KDM4EALDH1A1 | |
| SCHEMBL6791730 | 0.85 | NR1H2 (0.36) | NR1H2TSHRCYP3A4KDM4EALDH1A1 | |
| SCHEMBL3303354 | 0.82 | ATM (0.41) | TSHRCYP3A4KDM4EATMALDH1A1 | |
| SCHEMBL3305726 | 0.82 | ATM (0.41) | TSHRCYP3A4KDM4EATMALDH1A1 | |
| SCHEMBL31216673 | 0.81 | TSHR (0.43) | NR1H2TSHRCHRNB2CHRNA4ATM | |
| SCHEMBL6484163 | 0.81 | TSHR (0.38) | TSHRCHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953805-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050170999-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | FILLA SANDRA A (US) | 2005-08-04 | — | — | US | disclosed |
| US-6855725-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040082606-A1 | Excitatory amino acid receptor antagonists | KHAU VIEN VAN (US) | 2004-04-29 | — | — | US | disclosed |
| US-20040063749-A1 | Excitatory amino acid receptor antagonists | BLEISCH THOMAS JOHN (US) | 2004-04-01 | — | — | US | disclosed |
| EP-1351955-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1351952-A2 | PYRROLIDINYLMETHYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1351951-A2 | PYRROLIDINYLMETHYL- AND PIPERIDINYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002053561-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-07-11 | — | — | WO | disclosed |
| WO-2002053556-A2 | PYRROLIDINYLMETHYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-07-11 | — | — | WO | disclosed |
| WO-2002053555-A2 | PYRROLIDINYLMETHYL- AND PIPERIDINYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082606-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, SLC1A3 | NR1H2 1141/4885TSHR 375/4885CYP3A4 2286/4885 |
| US-20050170999-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | SLC1A2, SLC1A1, SLC1A3 | NR1H2 863/4885TSHR 807/4885CYP3A4 3320/4885 |
| US-20040063749-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, SLC1A3 | NR1H2 890/4885TSHR 524/4885CYP3A4 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.